Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα

Area of Science:

• Oncology
• Immunotherapy
• Melanoma Research

Background:

• Immune checkpoint blockade (ICB) is a standard melanoma treatment.
• Some patients progress despite ICB, necessitating alternative therapies.
• Adoptive transfer of tumor-infiltrating lymphocytes (TIL) shows promise for ICB-resistant melanoma.

Purpose of the Study:

• To evaluate the safety and efficacy of TIL therapy combined with Nivolumab.
• To investigate the impact of a pegylated interferon-alpha (IFNa) regimen on TIL plus Nivolumab therapy.
• To assess IFNa's role in conditioning and supporting patients with advanced melanoma.

Main Methods:

• A clinical trial (NCT03638375) involving patients with ICB-resistant stage III/IV melanoma.
• Patients received TIL plus Nivolumab, with or without IFNa conditioning and support.
• Safety and efficacy endpoints were monitored, including adverse events and disease control.

Main Results:

• The combination therapy was safe, with manageable side effects like lymphopenia and neutropenia.
• Disease control was significantly higher in patients receiving IFNa (41.7%) compared to those without (11.1%).
• IFNa treatment reduced circulating leukocytes and neutrophils, particularly in responders.

Conclusions:

• TIL therapy combined with Nivolumab and IFNa is a safe and clinically active treatment for advanced melanoma.
• The addition of IFNa enhances the efficacy of TIL and Nivolumab therapy.
• This low-toxicity regimen may be suitable for frail patients unable to tolerate intensive lymphodepleting therapies.